Eli Lilly (LLY) Non-Current Deferred Tax Liability (2018 - 2022)
Eli Lilly's Non-Current Deferred Tax Liability history spans 11 years, with the latest figure at $87.3 million for Q4 2022.
- For Q4 2022, Non-Current Deferred Tax Liability fell 94.96% year-over-year to $87.3 million; the TTM value through Dec 2022 reached $87.3 million, down 94.96%, while the annual FY2022 figure was $87.3 million, 94.96% down from the prior year.
- Non-Current Deferred Tax Liability reached $87.3 million in Q4 2022 per LLY's latest filing, down from $171.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $5.1 billion in Q4 2020 to a low of $87.3 million in Q4 2022.
- Average Non-Current Deferred Tax Liability over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2020.
- Peak YoY movement for Non-Current Deferred Tax Liability: skyrocketed 51.61% in 2019, then crashed 94.96% in 2022.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $3.0 billion in 2018, then surged by 51.61% to $4.6 billion in 2019, then rose by 10.13% to $5.1 billion in 2020, then plummeted by 65.81% to $1.7 billion in 2021, then plummeted by 94.96% to $87.3 million in 2022.
- Per Business Quant, the three most recent readings for LLY's Non-Current Deferred Tax Liability are $87.3 million (Q4 2022), $171.9 million (Q3 2022), and $862.5 million (Q2 2022).